Clinical outcome of patients with various advanced cancer types vaccinated with an optimized cryptic human telomerase reverse transcriptase (TERT) peptide: Results of an expanded phase II study

Annals of Oncology

Volumn 23, Issue 2, 2012, Pages 442-449

  Kotsakis, A ^a   Vetsika, E K ^b   Christou, S ^a   Hatzidaki, D ^a   Vardakis, N ^a   Aggouraki, D ^b   Konsolakis, G ^b   Georgoulias, V ^a,b   Christophyllakis, Ch ^c   Cordopatis, P ^d   Kosmatopoulos, K ^e   Mavroudis, D ^a,b  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b UNIVERSITY OF CRETE   (Greece)

^c KAT HOSPITAL   (Greece)

^d UNIVERSITY OF PATRAS   (Greece)

^e Vaxon Biotech   (France)

Author keywords

Cancer; Cryptic; Immunotherapy; Telomerase; Vaccine

Indexed keywords

AMINOTRANSFERASE; HLA A ANTIGEN; PEPTIDE VACCINE; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG; VX 001;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASTHENIA; AUTOIMMUNE DISEASE; CANCER CONTROL; CANCER IMMUNIZATION; CANCER PATIENT; CANCER SURVIVAL; CELL SPECIFICITY; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED STUDY; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NAUSEA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SKIN MANIFESTATION; SOLID TUMOR; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; CANCER VACCINES; FEMALE; HLA-A2 ANTIGEN; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; NEOPLASMS; TELOMERASE; TREATMENT OUTCOME;

EID: 84856324806     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr396     Document Type: Article

References (65)

1. Van Der Bruggen P, Zhang Y, Chaux P et al. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev 2002; 188: 51-64.
2. Nagorsen D, Scheibenbogen C, Marincola FM et al. Natural T cell immunity against cancer. Clin Cancer Res 2003; 9: 4296-4303.
3. Jager E, Ringhoffer M, Karbach J et al. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-Tcell responses: evidence for immunoselection of antigen-loss variants in vivo. Int J Cancer 1996; 66: 470-476.
4. Schmollinger JC, Vonderheide RH, Hoar KM et al. Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction. Proc Natl Acad Sci U S A 2003; 100: 3398-3403.
5. Wenandy L, Sorensen RB, Sengelov L et al. The immunogenicity of the hTERT540-548 peptide in cancer. Clin Cancer Res 2008; 14: 4-7.
6. Kim NW, Piatyszek MA, Prowse KR et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266: 2011-2015.
7. Hiyama E, Hiyama K. Telomere and telomerase in stem cells. Br J Cancer 2007; 96: 1020-1024.
8. Kumaki F, Kawai T, Hiroi S et al. Telomerase activity and expression of human telomerase RNA component and human telomerase reverse transcriptase in lung carcinomas. Hum Pathol 2001; 32: 188-195.
9. Wu TC, Lin P, Hsu CP et al. Loss of telomerase activity may be a potential favorable prognostic marker in lung carcinomas. Lung Cancer 2003; 41: 163-169.
10. Lu C, Soria JC, Tang X et al. Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers. J Clin Oncol 2004; 22: 4575-4583.
11. Fujita Y, Fujikane T, Fujiuchi S et al. The diagnostic and prognostic relevance of human telomerase reverse transcriptase mRNA expression detected in situ in patients with nonsmall cell lung carcinoma. Cancer 2003; 98: 1008-1013.
12. Komiya T, Kawase I, Nitta T et al. Prognostic significance of TERT expression in non-small cell lung cancer. Int J Oncol 2000; 16: 1173-1177.
13. Marchetti A, Bertacca G, Buttitta F et al. Telomerase activity as a prognostic indicator in stage I non-small cell lung cancer. Clin Cancer Res 1999; 5: 2077-2081.
14. Hahn WC, Stewart SA, Brooks MW et al. Inhibition of telomerase limits the growth of human cancer cells. Nat Med 1999; 5: 1164-1170.
15. Herbert B, Pitts AE, Baker SI et al. Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. Proc Natl Acad Sci U S A 1999; 96: 14276-14281.
16. Domchek SM, Recio A, Mick R et al. Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillance. Cancer Res 2007; 67: 10546-10555.
17. Brunsvig PF, Aamdal S, Gjertsen MK et al. Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Cancer Immunol Immunother 2006; 55: 1553-1564.
18. Bolonaki I, Kotsakis A, Papadimitraki E et al. Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide. J Clin Oncol 2007; 25: 2727-2734.
19. Moudgil KD, Sercarz EE. Can antitumor immune responses discriminate between self and nonself? Immunol Today 1994; 15: 353-355.
20. Cibotti R, Kanellopoulos JM, Cabaniols JP et al. Tolerance to a self-protein involves its immunodominant but does not involve its subdominant determinants. Proc Natl Acad Sci U S A 1992; 89: 416-420.
21. Gross DA, Graff-Dubois S, Opolon P et al. High vaccination efficiency of lowaffinity epitopes in antitumor immunotherapy. J Clin Invest 2004; 113: 425-433.
22. Theobald M, Biggs J, Hernandez J et al. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J Exp Med 1997; 185: 833-841.
23. Colella TA, Bullock TN, Russell LB et al. Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy. J Exp Med 2000; 191: 1221-1232.
24. Grossmann ME, Davila T, Celis T. Avoiding tolerance against prostatic antigens with subdominant peptide epitopes. J Immunother 2001; 24: 237-241.
25. O'Mahony D, Kummar S, Gutierrez ME. Non-small-cell lung cancer vaccine therapy: a concise review. J Clin Oncol 2005; 23: 9022-9028.
26. Parkhurst MR, Riley JP, Igarashi T et al. Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase. Clin Cancer Res 2004; 10: 4688-4698.
27. Mavroudis D, Bolonakis I, Cornet S et al. A phase I study of the optimized cryptic peptide TERT(572y) in patients with advanced malignancies. Oncology 2006; 70: 306-314.
28. Scardino A, Gross DA, Alves P et al. HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J Immunol 2002; 168: 5900-5906.
29. Hernandez J, Garcia-Pons F, Lone YC et al. Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells. Proc Natl Acad Sci U S A 2002; 99: 12275-12280.
30. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
31. Armitage P, Berry G. Statistical Methods in Medical Research, 3rd edition. Boston, MA: Blackwell Scientific Publications 1994.
32. Ayyoub M, Migliaccio M, Guillaume P et al. Lack of tumor recognition by hTERT peptide 540-548-specific CD8(+) T cells from melanoma patients reveals inefficient antigen processing. Eur J Immunol 2001; 31: 2642-2651.
33. Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4: 321-327.
34. Simon RM, Steinberg SM, Hamilton M et al. Clinical trial designs for the early clinical development of therapeutic cancer vaccines. J Clin Oncol 2001; 19: 1848-1854.
35. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10: 909-915.
36. Buyse M, Thirion P, Carlson RW et al. Relation between tumour response to firstline chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer. Lancet 2000; 356: 373-378.
37. Johnson JR, Williams G, Pazdur R. End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 2003; 21: 1404-1411.
38. Hoos A, Parmiani G, Hege K et al. A clinical development paradigm for cancer vaccines and related biologics. J Immunother 2007; 30: 1-15.
39. Wolchok JD, Hoos A, O'Day S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15: 7412-7420.
40. Colombo MP, Piconese S. Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer 2007; 7: 880-887.
41. Lechner MG, Liebertz DJ, Epstein AL. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol 2010; 185: 2273-2284.
42. Nemunaitis J, Jahan T, Ross H et al. Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer. Cancer Gene Ther 2006; 13: 555-562.
43. Gonzalez G, Crombet T, Torres F et al. Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy. Ann Oncol 2003; 14: 461-466.
44. Lonchay C, van der Bruggen P, Connerotte T et al. Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc Natl Acad Sci U S A 2004; 101(Suppl 2): 14631-14638.
45. Clark WH Jr., Elder DE, Guerry Dt et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989; 81: 1893-1904.
46. Marrogi AJ, Munshi A, Merogi AJ et al. Study of tumor infiltrating lymphocytes and transforming growth factor-beta as prognostic factors in breast carcinoma. Int J Cancer 1997; 74: 492-501.
47. Zhang L, Conejo-Garcia JR, Katsaros D et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348: 203-213.
48. Galon J, Costes A, Sanchez-Cabo F et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313: 1960-1964.
49. Kusmartsev SA, Li Y, Chen SH. Gr-1+ myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation. J Immunol 2000; 165: 779-785.
50. Melani C, Chiodoni C, Forni G, Colombo MP. Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood 2003; 102: 2138-2145.
51. Almand B, Clark JI, Nikitina E et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 2001; 166: 678-689.
52. Pandit R, Lathers DM, Beal NM et al. CD34+ immune suppressive cells in the peripheral blood of patients with head and neck cancer. Ann Otol Rhinol Laryngol 2000; 109: 749-754.
53. Bronte V, Serafini P, Apolloni E, Zanovello P. Tumor-induced immune dysfunctions caused by myeloid suppressor cells. J Immunother 2001; 24: 431-446.
54. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol 2004; 4: 941-952.
55. Kusmartsev S, Nagaraj S, Gabrilovich DI. Tumor-associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells. J Immunol 2005; 175: 4583-4592.
56. Vuk-Pavlovic S, Bulur PA, Lin Y et al. Immunosuppressive CD14+HLA-DRlow/-monocytes in prostate cancer. Prostate 2010; 70: 443-455.
57. Hoechst B, Ormandy LA, Ballmaier M et al. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology 2008; 135: 234-243.
58. Mandruzzato S, Solito S, Falisi E et al. IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. J Immunol 2009; 182: 6562-6568.
59. Liu CY, Wang YM, Wang CL et al. Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14-/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol 2009; 136(1): 35-45.
60. Srivastava MK, Bosch JJ, Thompson JA et al. Lung cancer patients' CD4(+) T cells are activated in vitro by MHC ll cell-based vaccines despite the presence of myeloid-derived suppressor cells. Cancer Immunol Immunother 2008; 57: 1493-1504.
61. Rodriguez PC, Ernstoff MS, Hernandez C et al. Arginase I-producing myeloidderived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res 2009; 69: 1553-1560.
62. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 1999; 10: 673-679.
63. Kolquist KA, Ellisen LW, Counter CM et al. Expression of TERT in early premalignant lesions and a subset of cells in normal tissues. Nat Genet 1998; 19: 182-186.
64. Nair SK, Heiser A, Boczkowski D et al. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med 2000; 6: 1011-1017.
65. Danet-Desnoyers GA, Luongo JL, Bonnet DA et al. Telomerase vaccination has no detectable effect on SCID-repopulating and colony-forming activities in the bone marrow of cancer patients. Exp Hematol 2005; 33: 1275-1280.